Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VATON: Vibegron add-on therapy for overactive bladder symptoms in BPH patients on alpha-1 blockers
jRCTs031230450Completed
- Sponsor
- Kyorin Pharmaceutical
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of vibegron in overactive bladder (OAB) and benign prostatic hyperplasia (BPH) (2 arms), sponsored by Kyorin Pharmaceutical. Primary endpoint: Primary: Change in OABSS total score at week 12. Started Dec 2023; status: completed.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on jRCTs031230450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230450.